Study guide
4.10 Results Delivery & Long-Term Follow-Up
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
4.10 Results Delivery & Long-Term Follow-Up
Key Takeaways Explain This Topic AI
Results delivery is a structured counseling process: prepare, disclose clearly, pause for emotion, explain meaning/limitations, negotiate next steps, and plan follow-up—not a one-way lab readout.
SPIKES-adjacent structure (setting, perception, invitation, knowledge, emotion, summary/strategy) adapts well to genetic disclosures when paired with genetics-specific content (inheritance, cascade, reclassification).
VUS disclosure must state uncertainty explicitly, avoid treating VUS as pathogenic for medical or cascade decisions, and include recontact/reanalysis plans when appropriate.
Long-term follow-up includes medical management handoffs, cascade testing outreach planning, psychosocial check-ins, and pathways for reclassification updates.
Board items often test pacing after bad news and correct framing of VUS versus pathogenic results.
Last updated: August 2026
Why results delivery is scored separately from “knowing the genetics”
You can interpret an ACMG classification correctly and still fail the counseling task if you flood a shocked parent with exon numbers, skip emotion, mis-sell a VUS as actionable, or end without a cascade and recontact plan. Domain 4B expects results delivery and long-term follow-up as deliberate skills: how news is given, how meaning is co-constructed, and how care continues after the visit.
A SPIKES-adjacent structure adapted to genetics
Oncology’s SPIKES protocol is a useful scaffold; genetics adds inheritance, reproductive implications, and family communication.
Step SPIKES idea Genetics adaptation
S — Setting Privacy, right people present, minimize interruptions Confirm modality privacy; ask whom they want present; silence phones; interpreter ready
P — Perception Elicit what they already believe/know “What have you been told to expect from this test?” Correct misconceptions gently later
I — Invitation Ask how much detail they want now Some want full gene lists; others need headline first—contract depth and pace
K — Knowledge Give information in small chunks Lead with bottom line (pathogenic / negative / VUS), then inheritance, risks, limitations
E — Emotion Respond to affect with empathy Silence, reflection, tissues; do not race to cascade logistics while sobbing peaks
S — Summary / Strategy Plan next steps Medical referrals, screening, reproductive options, cascade plan, follow-up timing, recontact
Breaking bad news: practical pacing
Warn shot: “I have the results, and they are not what we hoped” (when accurate).
Clear headline: “The test found a pathogenic variant in GENE that explains the cardiomyopathy in your family.”
Pause. Let silence work.
Check in: “What is going through your mind?”
Layered education: inheritance → personal implications → relatives → management → uncertainties.
Written summary and scheduled follow-up—memory for facts drops after emotional shock.
Avoid starting with methodology lectures (“Next-generation sequencing of 87 genes…”) before the headline. Avoid false reassurance (“At least we have an answer”) when grief is primary—validation first.
Result-type playbooks
Result type Disclosure emphasis Follow-up essentials
Pathogenic / likely pathogenic (P/LP) Diagnosis/risk explanation; management; inheritance; cascade Specialty referrals; screening calendar; family letter offer; psychosocial support
Negative (with residual risk) What was ruled out vs not; residual risk; any further testing When to revisit testing as technology/indication evolves
VUS Not proven disease-causing; usually not used for predictive testing of healthy relatives; may be reinterpreted Recontact policy; segregation studies if indicated; avoid irreversible decisions based on VUS alone
Secondary / unexpected findings Re-contract; separate from primary indication; consent context Extra time; ethics/consult as needed; careful documentation
Incidental carrier / pharmacogenetic Distinguish from diagnostic finding Reproductive counseling or medication implications as relevant
VUS disclosure—high-yield precision
Clients hear “variant” and think “mutation = disease.” Explicit language matters:
“This result is a variant of uncertain significance . Laboratories and clinicians do not have enough evidence to say it causes disease.”
“We do not typically test healthy relatives for a VUS to predict their future risk the way we would for a known pathogenic variant.”
“We will discuss whether additional information (family testing for segregation, data updates) could help later.”
Document client understanding and any disagreement with recommendations.
Trap answers treat VUS like P/LP for mastectomy decisions or urge all cousins to test for the VUS tomorrow.
Cascade follow-up planning
Cascade testing turns one result into family risk reduction—when the variant is clinically actionable.
- Planning element Counselor actions
- Who is at risk Review pedigree; prioritize first-degree then extend as indicated
What to tell Offer family letters with gene, variant nomenclature, lab, and counseling contacts—client controls disclosure timing
- How to access Site-specific testing vs familial variant test; insurance navigation pointers
- Barriers Estrangement, stigma, distance, language—problem-solve without forcing disclosure
- Documentation Note which relatives discussed; client’s communication plan; materials provided
Long-term follow-up is not only cascade: children aging into adult consent, pregnancy planning years later, reclassification letters, and surveillance adherence checks.
Long-term follow-up architecture
Think beyond “call if questions”:
Near-term (days–weeks): Emotional processing visit/call; clarify questions after shock; confirm appointments with cardiology/oncology/etc.
Medium-term (months): Cascade progress; adherence to screening; reproductive planning if relevant.
Long-term (years): Reanalysis/reclassification pathways; updated guidelines; transitioning adolescents to adult care.
Institutions vary on recontact obligations; exam-wise, recognize that discussing how updates would reach the client is part of good disclosure, especially for VUS and evolving gene–disease relationships.
Integrated scenarios
Scenario A — pediatric diagnosis: Parents freeze after hearing “pathogenic.” Best next move is empathic presence and invitation for questions—not immediately listing reproductive recurrence percentages unless they ask or contracting indicates readiness.
Scenario B — VUS in a cancer panel: Client asks, “Should my sister get a double mastectomy?” Answer clarifies VUS should not drive that decision; sister may still need counseling based on family history/empiric risk.
Scenario C — negative panel, strong history: Emphasize residual risk and empiric management; plan follow-up if new genes/methods arise; avoid “you’re in the clear forever.”
Scenario D — telephonic P/LP disclosure already done poorly elsewhere: Re-contract a dedicated disclosure/counseling visit; assess understanding and distress; rebuild strategy and cascade plan.
Common traps
Method dump before headline.
No pause after bad news.
Managing VUS as pathogenic for cascade predictive testing.
Ending without written summary or timed follow-up.
Taking over family disclosure against the client’s paced plan without an applicable duty-to-warn framework (ethics domain nuance).
Quick exam checklist
Setting and perception checked?
Headline clear; emotion addressed?
Result class (P/LP, neg, VUS) framed correctly?
Strategy includes medical next steps, cascade as appropriate, and longitudinal recontact/follow-up?